ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.910,92
-0,25%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Phathom Pharmaceuticals Inc (PHAT)

  7. Phathom Pharmaceuticals Inc (PHAT) News

PHAT

Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PHAT
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual MeetingNASDAQ:PHATPhathom Pharmaceuticals Inc
09/05/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PHATPhathom Pharmaceuticals Inc
09/05/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
09/05/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHATPhathom Pharmaceuticals Inc
29/04/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024NASDAQ:PHATPhathom Pharmaceuticals Inc
03/04/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PHATPhathom Pharmaceuticals Inc
26/03/202413h00GlobeNewswire Inc.Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”NASDAQ:PHATPhathom Pharmaceuticals Inc
07/03/202422h01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PHATPhathom Pharmaceuticals Inc
07/03/202414h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
07/03/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHATPhathom Pharmaceuticals Inc
29/02/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024NASDAQ:PHATPhathom Pharmaceuticals Inc
13/02/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
13/02/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial PatientsNASDAQ:PHATPhathom Pharmaceuticals Inc
31/01/202414h00GlobeNewswire Inc.Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:PHATPhathom Pharmaceuticals Inc
23/01/202402h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHATPhathom Pharmaceuticals Inc
15/12/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
14/12/202314h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
14/12/202314h00GlobeNewswire Inc.Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules CapitalNASDAQ:PHATPhathom Pharmaceuticals Inc
06/12/202314h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
06/12/202314h00GlobeNewswire Inc.Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERDNASDAQ:PHATPhathom Pharmaceuticals Inc
28/11/202314h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
28/11/202314h00GlobeNewswire Inc.Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated HeartburnNASDAQ:PHATPhathom Pharmaceuticals Inc
20/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHATPhathom Pharmaceuticals Inc
09/11/202322h02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PHATPhathom Pharmaceuticals Inc
09/11/202314h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PHATPhathom Pharmaceuticals Inc
09/11/202314h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PHATPhathom Pharmaceuticals Inc
09/11/202314h00GlobeNewswire Inc.Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business UpdatesNASDAQ:PHATPhathom Pharmaceuticals Inc
09/11/202301h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHATPhathom Pharmaceuticals Inc
03/11/202321h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PHATPhathom Pharmaceuticals Inc
01/11/202322h50Dow Jones NewsPhathom Pharmaceuticals Gets FDA Approval for Voquezna TreatmentNASDAQ:PHATPhathom Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PHAT

Kürzlich von Ihnen besucht

BIT
F19151
Vontobel Financial Produ...
EU
PACAT
Reg Provence Alpes Cote ...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten